anti-interleukin 21 (NNC0114-0006) in combination with liraglutide

anti-interleukin 21 (NNC0114-0006) in combination with liraglutide
Trade Name
Orphan Indication Type I Diabetes Mellitus with residual beta cell function
USA Market Approval USA
USA Designation Date 2017-01-12 00:00:00
Sponsor Novo Nordisk, Inc.;800 Scudders Mill Road, P. O. Box 846;New Jersey, 08536